SCOPUS 정보 검색 플랫폼

Regulatory Toxicology and Pharmacology

Volumn 43, Issue 2, 2005, Pages 134-140

Rating the severity of the medical consequences of drug-induced liver injury

(3) Slavin, D E a Schlichting, C L b Freston, J W c

a PFIZER GLOBAL RESEARCH AND DEVELOPMENT (United Kingdom)

b University of Connecticut Health Center ^* (United States)

c UNIVERSITY OF CONNECTICUT HEALTH CENTER (United States)

Author keywords

Adverse events; Hepatotoxicity; Liver function tests; Risk assessment; Risk benefit analysis

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADENOMA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; APRAXIA; ARTICLE; CHOLESTASIS; CLINICAL TRIAL; DELIRIUM; DISEASE SEVERITY; DRUG EFFECT; DRUG INDUCED DISEASE; EOSINOPHILIA; FATTY LIVER; HAZARD; HEPATIC COMA; HEPATITIS; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; JAUNDICE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LIVER ISCHEMIA; LIVER NECROSIS; LIVER VENOOCCLUSIVE DISEASE; NAUSEA; NECROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROBABILITY; PROTHROMBIN TIME; PRURITUS; RISK MANAGEMENT; SCLEROSING CHOLANGITIS; VOMITING;

CHROMANS; DATA COLLECTION; HEPATITIS, TOXIC; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; LIVER FUNCTION TESTS; QUESTIONNAIRES; RISK ASSESSMENT; THIAZOLIDINEDIONES;

EID: 26444469521 PISSN: 02732300 EISSN: 10960295 Source Type: Journal
DOI: 10.1016/j.yrtph.2005.07.002 Document Type: Article

Times cited : (7)

References (9)

1
- 18144429936
- FDA/CDER PhRMA/FDA/AASLD Drug-Induced Hepatotoxicity White Paper Postmarketing Considerations, 2000. http://www.fda.gov/cder/livertox/postmarket. pdf.
- (2000) FDA/CDER PhRMA/FDA/AASLD Drug-Induced Hepatotoxicity White Paper Postmarketing Considerations

2
- 26444519294
- Food and Drug Administration Rockville, MD
- D.J. Graham, and L. Green Final report: Liver failure risk with troglitazone. Office of Postmarketing Drug Risk Assessment. Center for Drug Evaluation and Research 2000 Food and Drug Administration Rockville, MD December 19
- (2000) Final Report: Liver Failure Risk with Troglitazone. Office of Postmarketing Drug Risk Assessment. Center for Drug Evaluation and Research
- Graham, D.J.¹ Green, L.²

3
- 0037259315
- Incidence of idiopathic acute liver failure and hospitalised liver injury in patients treated with troglitazone
- D.J. Graham, C.R. Drinkard, and D. Shatin Incidence of idiopathic acute liver failure and hospitalised liver injury in patients treated with troglitazone Am. J. Gastroenterol. 98 2003 175 179
- (2003) Am. J. Gastroenterol. , vol.98 , pp. 175-179
- Graham, D.J.¹ Drinkard, C.R.² Shatin, D.³

4
- 26444458431
- The tolerability of risk from nuclear power stations
- Suffolk CO10 6FS.
- Health and Safety Executive, 1992. The tolerability of risk from nuclear power stations. HSE Books: Sudbury, Suffolk CO10 6FS.
- (1992) HSE Books: Sudbury

5
- 0033366695
- Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents
- S.S. Jick, M. Stender, and M.W. Myers Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents Diabetes Care 22 1999 2067 2071
- (1999) Diabetes Care , vol.22 , pp. 2067-2071
- Jick, S.S.¹ Stender, M.² Myers, M.W.³

6
- 0037133533
- Did this drug cause my patient's hepatitis?" and related questions
- D.W. Nierenberg Did this drug cause my patient's hepatitis?" and related questions Ann. Intern. Med. 19 136 2002 480 483
- (2002) Ann. Intern. Med. , vol.19 , Issue.136 , pp. 480-483
- Nierenberg, D.W.¹

7
- 0037126649
- Acute Liver Failure Study Group, Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States
- G. Ostapowicz, R.J. Fontana, F.V. Schiodt, A. Larson, T.J. Davern, S.H. Han, T.M. McCashland, A.O. Shakil, J.E. Hay, L. Hynan, J.S. Crippin, A.T. Blei, G. Samuel, J. Reisch, and W.M. Lee Acute Liver Failure Study Group, Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States Ann. Intern. Med. 137 2002 947 954
- (2002) Ann. Intern. Med. , vol.137 , pp. 947-954
- Ostapowicz, G.¹ Fontana, R.J.² Schiodt, F.V.³ Larson, A.⁴ Davern, T.J.⁵ Han, S.H.⁶ McCashland, T.M.⁷ Shakil, A.O.⁸ Hay, J.E.⁹ Hynan, L.¹⁰ Crippin, J.S.¹¹ Blei, A.T.¹² Samuel, G.¹³ Reisch, J.¹⁴ Lee, W.M.¹⁵

8
- 26444488690
- Westfields Conference Center Chantilly, VA
- R. Temple Drug-Induced Liver Injury Impacts on the Food and Drug Administration (FDA). FDA Conference - Drug-Induced Liver Injury: A National and Global Problem 12-13 February 2001 2001 Westfields Conference Center Chantilly, VA
- (2001) Drug-Induced Liver Injury Impacts on the Food and Drug Administration (FDA). FDa Conference - Drug-Induced Liver Injury: A National and Global Problem 12-13 February 2001
- Temple, R.¹

9
- 0033645002
- Thiazolidinedione hepatotoxicity: A class effect?
- K.G. Tolman Thiazolidinedione hepatotoxicity: a class effect? Int. J. Clin. Pract. 113 2000 29 34
- (2000) Int. J. Clin. Pract. , vol.113 , pp. 29-34
- Tolman, K.G.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.